Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propylthiouracil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPO known ✓ | P07202 | 1/20 | 0.61 |
| ▸ | LPO | P22079 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYB5R3 | P00387 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiouracil SCHEMBL28203909 | 0.82 | TP53 (0.54) | LPOMPOTPOTSHRCYP2C19 | |
| SCHEMBL41241 | 0.81 | KDM1A (0.39) | LPOKMT2ASMN1; SMN2ALDH1A1PTGS1 | |
| SCHEMBL27672161 | 0.81 | KDM1A (0.39) | LPOKMT2ASMN1; SMN2ALDH1A1PTGS1 | |
| Phosphine SCHEMBL27662410 | 0.80 | KDM1A (0.38) | LPOKMT2ASMN1; SMN2ALDH1A1PTGS1 | |
| Propylthiouracil SCHEMBL41239 | 0.78 | LPO (1.00) | LPOMPOTPOTSHRCYP2C19 | |
| Propylthiouracil SCHEMBL5493716 | 0.78 | LPO (1.00) | LPOMPOTPOTSHRCYP2C19 | |
| Propylthiouracil SCHEMBL27995248 | 0.77 | LPO (0.96) | LPOMPOTPOTSHRCYP2C19 | |
| SCHEMBL13723726 | 0.76 | KDM1A (0.39) | MAPTSMN1; SMN2ALDH1A1HPGD | |
| Thiourea SCHEMBL29139740 | 0.74 | KDM1A (0.35) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL10616922 | 0.72 | MAPT (0.43) | MAPTSMN1; SMN2ALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070048282-A1 | With improved shelf life and storage stability; expression vectors and host cells; therapeutic proteins are chemically or genetically fused to albumin | HUMAN GENOME SCIENCES, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20020119519-A1 | Nucleotide sequences coding preferential polyeptide for use in the treatment of cancer, kidney and respiratory disorders | HUMAN GENOME SCIENCES, INC. | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070048282-A1 | With improved shelf life and storage stability; expression vectors and host cells; therapeutic proteins are chemically or genetically fused to albumin | ALB, HSPA5, HAVCR2 | TPO 4273/4885LPO 2441/4885MPO 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.